PACAP/VIP Glycopeptide Agonists as Neuroprotective Therapies for Parkinson's Disease

Medicine & Life Sciences

1. Animal Models 19%
2. Blood-Brain Barrier 25%
3. Brain 32%
4. CHO Cells 15%
5. Clinical Trials 8%
6. Dopamine 22%
7. Dopaminergic Neurons 27%
8. Drug Development 12%
9. Drug Stability 18%
10. Firearms 15%
11. Glycopeptides 66%
12. Immunomodulation 15%
13. Inflammation 7%
14. Intercellular Signaling Peptides and Proteins 43%
15. Mass Spectrometry 11%
16. Microdialysis 14%
17. Neurodegenerative Diseases 11%
18. Neuroprotection 27%
19. Parkinson Disease 100%
20. Peptides 8%
21. Pharmaceutical Preparations 10%
22. Pituitary Adenylate Cyclase-Activating Polypeptide 92%
23. Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide, Type I 21%
24. Receptors, Vasoactive Intestinal Peptide, Type II 22%
25. Receptors, Vasoactive Intestinal Polypeptide, Type I 21%
26. Rodentia 10%
27. Secretin 16%
28. Surface-Active Agents 13%
29. Technology 8%
30. Therapeutics 6%
31. Vasoactive Intestinal Peptide 61%
32. Walking 11%